The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Cellular Phenotyping in Human iPSCS from the PPMI Cohort, 2023Studying Microglia Produced from Cell Lines Obtained from the Parkinson’s Progression Markers Initiative
Study Rationale: We have previously studied how different genetic variants associated with Parkinson’s disease (PD) affect dopamine neurons, which are the brain cells that degenerate in this disease...
-
Therapeutic Pipeline Program, 2023Evaluation of the Inflammation-blocking Drug Tolebrutinib as a Novel Disease-modifying Therapeutic for Parkinson's Disease
Study Rationale: Our project will test the effectiveness of a new treatment for Parkinson’s disease (PD). Developed by Sanofi, the drug — called Tolebrutinib — blocks inflammation in the brain. Based...
-
Research Grant, 2023Developing Wiring Diagrams of the Brain-Body Connection
Study Rationale: Individuals with Parkinson’s disease (PD) can show a variety of symptoms, including: resting tremors, alterations in directed hand movements, and treatment-induced dyskinesias; loss...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Developing Small Molecules to Enhance Autophagy and Clear Alpha-synuclein Aggregates as a Treatment for Parkinson’s Disease
Study Rationale: Autophagy is a process by which cells dispose of damaged or improperly functioning cell components. Recent evidence points at defects in autophagy as a feature of Parkinson’s disease...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Characterizing Region-specific Lipid Profiles in Parkinson’s Disease and Gaucher Disease
Study Rationale: Mutations in the GBA1 gene, which encodes glucocerebrocidase (GCase), is the most prevalent risk factor for Parkinson’s disease (PD). The resulting deficit in GCase activity leads to...
-
Therapeutic Pipeline Program, 2023Developing A Small-Molecule Activator of AMPK for the Treatment of Parkinson’s Disease
Study Rationale: Overwhelming evidence indicates that mitochondrial dysfunction contributes to the development of Parkinson’s disease (PD). We discovered that drugs that activate the enzyme AMPK...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.